secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0000950170-23-041578
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology to merge with Apexigen in stock deal; Pyxis shareholders to own 90% of combined company
--------------------------------------------------------------------------------

- Exchange ratio: 0.1725 Pyxis shares per Apexigen share; combined ownership ~90% Pyxis, ~10% Apexigen.
- Estimated purchase price ~$15.1M based on Pyxis closing price of $3.19 on June 5, 2023.
- Pro forma combined net loss for FY2022: $158.9M; for Q1 2023: $25.3M.
- Pro forma combined cash and marketable securities ~$161.4M as of March 31, 2023.
- Apexigen options, RSUs, and warrants assumed and converted with substantially similar terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/0000950170-23-041578-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023041578/pyxs-20230811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041578

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer